Vue.component('pdc-ra-overview', { template: '
The percentage of individuals 18 years and older with rheumatoid arthritis (RA) who met the Proportion of Days Covered (PDC) threshold of 80% during the measurement year for biologic medications used to treat RA.
' + 'A higher rate indicates better performance.
' + 'Intended Use
' + 'Performance measurement for health plans.
' + 'Data Sources
' + 'Prescription claims data.
' + 'Denominator
' + 'Individuals with both of the following:
' + 'Exclusions
' + 'Hospice or use of infused biologic medications used to treat RA.
' + 'Numerator
' + 'Individuals who met the PDC threshold of 80% during the measurement year.
' + 'Rheumatoid arthritis (RA) is a chronic and progressive inflammatory disease that can lead to premature mortality and reduce a person's health and quality of life.
RA is also a significant driver of costs for both treatment of the disease and its complications, causing a substantial impact on both direct healthcare costs and indirect costs associated with productivity loss, absenteeism, and disability.
Most RA patients require continuous treatment to control flares and disease progression.
The full benefits of self-injectable biologic treatments can only be achieved when patients are adherent to their medication regimen; however, many patients have difficulty taking their medications as often as directed. Nonadherent populations have been shown to be at a higher risk of flare-up, and overall, they experience more frequent flares compared to those who were more adherent to therapy.